Liposomal Doxorubicin
Liposomal Doxorubicin is a pharmaceutical drug with 56 clinical trials. Currently 10 active trials ongoing. Historical success rate of 63.6%.
Success Metrics
Based on 21 completed trials
Phase Distribution
Phase Distribution
14
Early Stage
28
Mid Stage
11
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
58.3%
21 of 36 finished
41.7%
15 ended early
10
trials recruiting
56
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma
Clinical Trials (56)
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma
Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma
Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes
Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
A Study of Liposomal Doxorubicin+Docetaxel+Trastuzumab+Metformin in Operable and Locally Advanced HER2 Positive Breast Cancer
Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer
MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer
Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma
AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours
AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer
Camrelizumab in Combination With PLD and Losartan in Patients With TNBC Who Have Received ≦ 1 Line of Chemotherapy
A Registry Study in Lymphoma Patients Treated With Liposomal Doxorubicin
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 56